Edition:
United States

Amarin Corporation PLC (AMRN.A)

AMRN.A on American Stock Exchange

2.30USD
22 Sep 2015
Change (% chg)

-- (--)
Prev Close
$2.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

Latest Key Developments (Source: Significant Developments)

Amarin appoints Michael Kalb chief financial officer
Thursday, 30 Jun 2016 07:30am EDT 

Amarin Corporation Plc : Amarin appoints Michael Kalb chief financial officer .Kalb joins Amarin from Taro Pharmaceutical Industries Ltd.  Full Article

Amarin Corporation PLC scores early victory in fish oil drug marketing lawsuit - Reuters
Thursday, 6 Aug 2015 08:00pm EDT 

Amarin Corporation PLC:Says A U.S. judge on Friday barred the U.S. Food and Drug Administration from stopping Irish drugmaker Amarin Corp from promoting its fish oil drug for off-label uses, saying the company is protected by the First Amendment - Reuters.Says the pharmaceutical industry has been watching this case because it is one of the first to raise a First Amendment argument in defense of promoting drugs for uses the FDA has not approved.Says the order by U.S. District Judge Paul Engelmayer in Manhattan means Amarin can promote its Vascepa pill to doctors for off-label use as long as it does so truthfully.Says the FDA has approved Vascepa to treat patients with very high levels of blood fats known as triglycerides that have been linked to diabetes, kidney failure and pancreatic cancer.Says the FDA has approved Vascepa to treat patients with very high levels of blood fats known as triglycerides that have been linked to diabetes, kidney failure and pancreatic cancer.Says Amarin sued the FDA in May shortly after the agency refused to approve the drug for statin patients.  Full Article

Amarin Corporation PLC announces $52.8 mln private placement
Friday, 6 Mar 2015 05:00am EST 

Amarin Corporation PLC:Enters into definitive securities subscription agreement for private placement of up to maximum of $52,822,618.50 of restricted American Depositary Shares, each representing one share of Amarin's Series A Convertible Preference Shares, par value £0.05 per share.Says for each restricted American Depositary Share, investors have agreed to pay a negotiated price of $0.15, resulting in $52,822,618.50 in aggregate gross proceeds.Each ten Series A convertible preference shares may be consolidated and redesignated as one ordinary share, par value £0.50 per share.Maximum of 35,215,079 ordinary shares, each represented by American Depositary Shares (ADSs) are issuable upon the consolidation and redesignation of the Series A Convertible Preference Shares.Intends to use net proceeds from this private placement primarily to support commercialization of Vascepa (icosapent ethyl) capsules, to advance it's Reduce-IT cardiovascular outcomes trial and for general corporate and working capital purposes.  Full Article

Amarin Corp and Eddingpharm announce agreement to develop and commercialize Vascepa (icosapent ethyl) in China
Thursday, 26 Feb 2015 09:16am EST 

Amarin Corporation PLC and Eddingpharm:Says an exclusive agreement for Eddingpharm to develop and commercialize Vascepa in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan.For uses that are currently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa.  Full Article

Amarin updates on ANCHOR trial SPA agreement rescission appeal
Friday, 12 Sep 2014 09:00am EDT 

Amarin Corporation PLC:Says U.S. Food and Drug Administration( FDA) rejects appeal of FDA's rescission of ANCHOR clinical trial Special Protocol Assessment (SPA) agreement.  Full Article

BRIEF-Amarin appoints Michael Kalb chief financial officer

* Kalb joins Amarin from Taro Pharmaceutical Industries Ltd Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)